Navigation Links
Arpida adds novel antibiotic AR-2474 to its preclinical pipeline

In vitro microbiology and proof of concept in topical models of infection

REINACH / BASEL, Switzerland, 8 March 2007 - Arpida Ltd. (SWX: ARPN) today announced positive results of in vitro microbiological studies with AR-2474 against a large panel of clinical isolates, including those resistant to various current therapies. In addition, topical applications of AR-2474 were found to be highly effective in eradicating methicillin resistant Staphylococcus aureus (MRSA) in preclinical models of skin infection and nasal carriage. AR-2474 is a novel antibiotic that is not affected by mechanisms of resistance to other antibiotics, e.g. mupirocin, fusidic acid, erythromycin and clindamycin.

The microbiological studies investigated the activity of AR-2474 against a panel of bacteria known to cause topical infections, e.g., skin, eye etc. The study was performed on 100 clinical isolates with various resistance patterns. The panel included 21 MRSA, 27 coagulase-negative staphylococci (CNS), 24 group A streptococci (GAS) and 28 pneumococci. The compound exhibited potent activity against all of the isolates and this activity was unaffected by any pre-existing mechanism of resistance.

Additionally, AR-2474 has been shown to be bactericidal and exhibit little or no propensity for the development of resistance. The antibacterial activity and potency of AR-2474 was also confirmed in vivo against topical gold standard mupirocin (Bactroban®) in two distinct preclinical models of MRSA infection of the skin and MRSA nasal carriage. In both models, a preliminary topical formulation of AR-2474 was at least as efficacious as mupirocin. Dr. Sergio Lociuro, Head of Research at Arpida Ltd. commented, "AR-2474 originates from our own research discovery programs and has now progressed to an advanced pre-clinical stage of development. We aim to develop AR-2474 as a topical therapy for different indications including the prevention of MRSA transmission. In recent years, topical antibiotics like mupirocin have been extensively used in the healthcare setting to limit the transmission of MRSA. MRSA and other microbes have become increasingly resistant to many topical antibiotics, thus representing a significant emerging clinical issue that requires to be addressed with novel therapies."
- ends -

For further information please contact: Arpida Dr Khalid Islam, President and CEO Harry Tel: + 41 61 417 96 Welten, MBA, CFO and Senior Vice President Paul 60 Tel: + 41 61 417 96 Verbraeken, Head of Corporate Communications 65 Tel: + 41 61 417 96 83

About Arpida Ltd.
Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel antibiotic drugs that seek to overcome the growing problem of bacterial resistance. Arpida's leading product candidate is intravenous iclaprim, a broad-spectrum antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). In November 2006, intravenous iclaprim has successfully completed its first Phase III trial in the treatment of cSSSI (complicated skin and skin structure infections). The US Food and Drug Administration has granted fast track status to intravenous iclaprim for the treatment of cSSSI. An oral formulation of iclaprim has successfully completed three Phase I trials: a radiolabelled ADME study (absorption, distribution, metabolism and excretion), a Phase I bioavailability trial with a solution and one with a capsule formulation. Arpida believes that the availability of an oral formulation could potentially fulfil an important clinical medical need for the treatment of serious bacterial infections, particularly those caused by MRSA. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situat ions, but also as an oral formulation, allowing early patient discharge and outpatient treatment.

This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort. Arpida's third most advanced programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against 611 pneumococcal clinical isolates from Europe, the USA and Asia irrespective of the mechanisms of resistance to currently used drugs. Arpida received authorisation to enter first-in-man studies with AR-709 in the UK in the second half of 2006. An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating MRSA in preclinical models of skin infection and nasal carriage. Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


'"/>




Related medicine technology :

1. Arpida Announces Promising Results of "First-In-Man" Studies With AR-709
2. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
3. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):